Edition:
India

Kitov Pharma Ltd (KTOV.OQ)

KTOV.OQ on NASDAQ Stock Exchange Capital Market

4.06USD
25 Sep 2020
Change (% chg)

$0.07 (+1.75%)
Prev Close
$3.99
Open
$3.94
Day's High
$4.09
Day's Low
$3.91
Volume
55,943
Avg. Vol
288,303
52-wk High
$14.40
52-wk Low
$2.20

Select another date:

Sat, Jul 11 2020

BRIEF-Kitov Pharma Files Stock Shelf Of Up To 28 Million Adss By Selling Shareholders

* KITOV PHARMA LTD FILES STOCK SHELF OF UP TO 28 MILLION ADSS BY SELLING SHAREHOLDERS - SEC FILING Source text (https://bit.ly/3027qaW) Further company coverage:

BRIEF-Kitov Announces Initiation Of Phase 1/2 Clinical Trial Of NT219 In Advanced Cancer Patients

* KITOV ANNOUNCES INITIATION OF PHASE 1/2 CLINICAL TRIAL OF NT219 IN ADVANCED CANCER PATIENTS

BRIEF-Kitov Pharma Receives Notice Of Intention To Grant A European Patent Covering Cm24, Its Anti-Ceacam1 Antibody

* KITOV PHARMA RECEIVES NOTICE OF INTENTION TO GRANT A EUROPEAN PATENT COVERING CM24, ITS ANTI-CEACAM1 ANTIBODY

BRIEF-Kitov Pharma Issues CEO Shareholder Letter Providing Business Update

* KITOV PHARMA ISSUES CEO SHAREHOLDER LETTER PROVIDING BUSINESS UPDATE

BRIEF-Kitov Announces $35.0 Million Registered Direct Offering

* KITOV PHARMA - ENTERED INTO DEFINITIVE AGREEMENTS WITH INVESTORS FOR PURCHASE, SALE OF 38.9 MILLION ADSS, WARRANTS TO PURCHASE UP TO 19.44 MILLION ADSS

BRIEF-Kitov Announces U.S. FDA Acceptance Of Investigational NDA To Conduct Phase 1/2 Clinical Trial Of NT219 In Multiple Types Of Advanced Cancer Patients

* KITOV ANNOUNCES U.S. FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION TO CONDUCT PHASE 1/2 CLINICAL TRIAL OF NT219 IN MULTIPLE TYPES OF ADVANCED CANCER PATIENTS

BRIEF-Kitov Reports U.S. Commercial Launch Of Consensi

* KITOV ANNOUNCES U.S. COMMERCIAL LAUNCH OF CONSENSI™ Source text for Eikon: Further company coverage:

BRIEF-Kitov To Present Phase 1 Data On Cm-24 In Patients With Advanced Cancer At ASCO 2020 Virtual Scientific Program

* KITOV TO PRESENT PHASE 1 DATA ON CM-24 IN PATIENTS WITH ADVANCED CANCER AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2020 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Kitov Pharma Files Prospectus Related To Offering Of 38.4 Million ADSs Each Representing 1 Ordinary Share

* KITOV PHARMA LTD - FILES PROSPECTUS RELATED TO OFFERING OF 38.4 MILLION ADSS EACH REPRESENTING 1 ORDINARY SHARE Source text: (https://bit.ly/3dF3kLh) Further company coverage:

BRIEF-Sabby Management LLC Reports 8.72% Passive Stake In Kitov Pharma Ltd

* SABBY MANAGEMENT LLC REPORTS 8.72% PASSIVE STAKE IN KITOV PHARMA LTD AS OF MAY 6 - SEC FILING Source text : (https://bit.ly/3b9msiP) Further company coverage:

Select another date: